menu
    • menu
    [{"orgOrder":0,"company":"Aspect Biosystems","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Aspect Biosystems","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aspect Biosystems \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Aspect Biosystems \/ Novo Nordisk"},{"orgOrder":0,"company":"Aspect Biosystems","sponsor":"Dimension","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Aspect Biosystems","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Aspect Biosystems \/ Dimension","highestDevelopmentStatusID":"3","companyTruncated":"Aspect Biosystems \/ Dimension"}]

    Find Clinical Drug Pipeline Developments & Deals by Vils Pharma Coating

    Menu

    Vils Pharma Coating

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aspect Biosystems

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Aspect Biosystems

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Sponsor : Dimension

                            Deal Size : $115.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Aspect Biosystems Raises $115M Series B for Bioprinted Tissue Therapeutics

                            Details : The financing will enable Aspect to advance multiple bioprinted tissue therapeutics toward the clinic for people living with metabolic and endocrine diseases.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Sponsor : Dimension

                            Deal Size : $115.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aspect Biosystems

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Aspect Biosystems

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Novo Nordisk

                            Deal Size : $2,675.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aspect Biosystems And Novo Nordisk Enter Partnership To Develop Bioprinted Tissue Therapeutics For Diabetes An...

                            Details : Under the terms of the agreement, Novo Nordisk will receive an exclusive, worldwide licence to use Aspect’s bioprinting technology to develop bioprinted tissue therapeutics including up to four products for the treatment of diabetes and obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $75.0 million

                            December 04, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Novo Nordisk

                            Deal Size : $2,675.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth